EVOTEC FOCUS SESSION
Advancing Drug Discovery Through Precision Medicine
Date: 14th June
Time: 8.30am - 11.00am EDT
Location: 254, Level 2
Development of effective therapeutics for neurological disorders has historically been challenging due to limited understanding of complex disease pathology and lack of accurate model systems in which to investigate disease etiology. Despite major activities over the past decades, one of the major challenges in CNS drug development remains translation. Recent technological advances in the field of multi-omics profiling, patient centric molecular diagnostics, in vitro patient stratification and iPSC disease modelling have now made it possible to identify the variation and mechanisms underlying a patient's disease and hold great promise for the development of more efficacious and safer drugs. With this focus session we would like to give both academic and industry partners the opportunity to share their perspective on this rapidly evolving field of precision medicine that could provide a better understanding of complex diseases on a molecular level and shift the one-fits-all drug discovery paradigm towards precision drugs.
Focus Area Agenda
8:30 - 8:45
Welcome remarks and overview: Advancing drug discovery through precision medicine
Bastian Zimmer, Evotec, Germany and Sandra Lubitz, Evotec, Germany
8:45 - 9:10
From big data to precision medicine drug discovery
Tim Ahfeldt, Recursion, USA
9:10 - 9:35
Development of first-in-class hipsc-neuron tau seeding models of endogenous tau aggregation
Ian Weidling, AbbVie, USA
9:35 - 10:00
Using personalized ipsc models to refine disease mechanisms and therapeutic approaches in als
Evangelos Kiskinis, Northwestern University, USA
10:00 - 10:25
Title to be confirmed
Lorenz Studer, MSKCC, USA
10:25 - 10:50
Unlocking the full potential of precision medicine approaches to patient care
Abigail Mariga, Bristol Myers Squibb, USA
10:50 - 11:00
Q&A and session wrap up
Evotec Scientific Posters
Developing iPSC-derived macrophages (iMACs) for off-the-shelf cell therapy - a versatile new cell type in the EVOcells platform for immune-oncology and beyond
Presented by: Kathrin Haake, Research Scientist, iPSC Cell Therapy
Poster number: 252
Time: 6.45 - 7.30pm EDT
Date: Wednesday 14th June
In this poster, we present our scalable 3D differentiation process to efficiently differentiate iMACs using a GMP-grade iPSC line. To ensure reproducible high quality and safety of our cell product, we perform stringent monitoring of all process stages using flow cytometry, transcriptome analysis (scRNAseq), as well as functional assays comparing iMACs to blood-derived counterparts.
Immune shielded and safe iPSC-derived cardiomyocytes for heart repair
Presented by: Kathrin Ridders, Senior Research Scientist, iPSC Cell Therapy
Poster number: 115
Time: 1.15 - 2.00pm EDT
Date: Friday 16th June
Evotec presents its off-the-she lf iPSC-cardiomyocyte therapeutic (iCM) to remuscularize the failing heart. Our productis genetically engineered to evade immune cell-mediated rejection combined with a drug inducible kill-switch and an anti-arrhythmia strategy. We developed a robust, scalable and GMP-compatible 3D differentiation process yielding highly pure iCM and demonstrate their functionality in vitro.
Development of an off-the-shelf allogenic anti-cancer cell therapy using potent iPSC-derived natural killer cells
Presented By: Davide Grandolfo, Research Scientist, iPSC Cell Therapy
Poster number: 139
Time: 1.15 - 2.00pm EDT
Date: Friday 16th June
Using our scalable EVOcells iNK differentiation process, we generate highly pure and potent iNK cells. Genetic modification of a GMP iPSC line and subsequent differentiation results in CAR-iNKs with strong target-specific cytotoxic activity against primary tumor samples and tumor cell lines in vitro, indicating their great potential as an alternative to autologous CAR cell therapies.
Evotec attendees
|
|
|
|
|
|
|
|
|
